Join
Live feed
·
PRReleasevia Quantisnow
Aileron Therapeutics Inc. logo

Aileron Therapeutics to Present Previously Announced Data from the Phase 1b Clinical Trial Evaluating Low-Dose LTI-03 in Idiopathic Pulmonary Fibrosis (IPF) at the 22nd International Colloquium on Lung and Airway Fibrosis

ByQuantisnow·Wall Street's wire, on your screen.
ALRN· Aileron Therapeutics Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track ALRN (Aileron Therapeutics Inc.) and more on Quantisnow.